Medical Insights
Breakthrough Device: Expedited Review, Not Investment Validation
An FDA Breakthrough Device Designation is just a process signal, it flags an expedited review route.…
Medical Insights
An FDA Breakthrough Device Designation is just a process signal, it flags an expedited review route.…
Medical Insights
When you’re evaluating a cardiac AI program, looking at the top-line outcomes isn’t enough. You have…
Medical Insights
Override rates in cardiac AI are the ultimate proof of a model’s real-world efficacy. It’s the…
Medical Insights
When you look at the FDA device record, one area jumps out: cardiac AI. It’s got…
Medical Insights
There’s a real gap between a cardiac AI vendor’s regulatory clearance claims and its measured accuracy…
Medical Insights
The FDA’s De Novo Classification process is the regulatory pathway for any truly novel medical device,…
Medical Insights
A regulatory clearance just marks the start of the real review, with the FDA’s recorded De…
Medical Insights
Cardiac AI Regulatory Safety frames model change as a regulatory question. When you’re dealing with a…
Medical Insights
The safety of a cardiac AI hinges on how its output actually gets used by a…
Medical Insights
Demographic coverage isn’t an academic idea. It’s a measurable property of an AI model’s validation evidence.…